Photocure ASA
OSE:PHO
Photocure ASA
Inventory
Photocure ASA
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Photocure ASA
OSE:PHO
|
Inventory
kr39.5m
|
CAGR 3-Years
13%
|
CAGR 5-Years
19%
|
CAGR 10-Years
12%
|
|
|
V
|
Vistin Pharma ASA
OSE:VISTN
|
Inventory
kr76.7m
|
CAGR 3-Years
21%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
N
|
Navamedic ASA
OSE:NAVA
|
Inventory
kr81.9m
|
CAGR 3-Years
10%
|
CAGR 5-Years
21%
|
CAGR 10-Years
2%
|
|
|
S
|
SoftOx Solutions AS
OSE:SOFTX
|
Inventory
kr0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Photocure ASA
Glance View
Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. The company is headquartered in Oslo, Oslo. The company went IPO on 2000-05-29. The company operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The firm is a parent of a wholly owned entity, Photocure Inc.
See Also
What is Photocure ASA's Inventory?
Inventory
39.5m
NOK
Based on the financial report for Dec 31, 2024, Photocure ASA's Inventory amounts to 39.5m NOK.
What is Photocure ASA's Inventory growth rate?
Inventory CAGR 10Y
12%
Over the last year, the Inventory growth was 6%. The average annual Inventory growth rates for Photocure ASA have been 13% over the past three years , 19% over the past five years , and 12% over the past ten years .
You don't have any saved screeners yet